Observational studyBMC endocrine disorders2026
Effects of orlistat on APRI and FIB-4 scores in patients with obesity: a retrospective observational study.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetabolic dysfunction–associated steatotic liver disease (MASLD) is closely associated with obesity and diabetes mellitus (DM). Early identification of patients at risk of liver fibrosis is important for clinical management; however, liver biopsy is not routinely feasible, and fibrosis is therefore assessed using non-invasive surrogate indices. Orlistat is a widely used therapy for obesity, but its effects on non-invasive liver fibrosis scores remain unclear. This study aimed to evaluate changes in calculated fibrosis scores after orlistat treatment in patients with obesity.
methodsData were retrospectively collected from 335 patients diagnosed with obesity who initiated orlistat treatment. Laboratory parameters and body weight measurements were obtained at the baseline, and at the 3rd, 6th, and 12th months following orlistat treatment. Weight changes were also recorded. MASLD not confirmed by biopsy was evaluated using calculated fibrosis scores. The Fibrosis-4 (FIB-4) index and Aspartate Transaminase-Platelet Ratio Index (APRI) are used to assess fibrosis, and the data were also obtained at the same endpoints.
resultsOf the 335 patients at baseline, data were available for 310, 134, and 39 patients at 3, 6, and 12 months, respectively. A significant reduction in weight and body mass index (BMI) was observed following orlistat treatment (p < 0.01). Repeated-measures analysis showed no significant change in FIB-4 scores (p = 0.46), whereas APRI scores decreased significantly (p < 0.01). When patients were stratified by a 5% weight-loss threshold, no differential effect on changes in FIB-4 or APRI scores was observed. In multiple linear regression analysis, changes in fibrosis scores were independent of sex, baseline weight, weight change during follow-up, presence of diabetes mellitus, and use of metformin or sodium–glucose cotransporter-2 inhibitors.
conclusionOrlistat treatment resulted in significant weight loss and reductions in ALT and AST levels. While the APRI score decreased significantly with treatment, the FIB-4 score did not change significantly. The change in APRI score was independent of weight loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.